SCHEMBL3557010

SCHEMBL3557010

Cc1cc(NC(=O)NCCN2CCC(c3ccccc3)CC2)cc(C)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.52
PRMT6 Q96LA8 1/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
POLB P06746 1/20 0.52
PRCP P42785 1/20 0.52
MAPK1 P28482 2/20 0.51
SLC18A3 Q16572 1/20 0.50
MAPT P10636 1/20 0.50
DRD3 P35462 2/20 0.49
DRD2 P14416 2/20 0.49
DRD4 P21917 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ADRA1D P25100 1/20 0.48
ADRA1A P35348 1/20 0.48
ADRA1B P35368 1/20 0.48
RAB9A P51151 1/20 0.48
TP53 P04637 1/20 0.48
HTR1A P08908 1/20 0.47
KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3556275 0.92 MAPK1 (0.47) CARM1PRMT6MEN1KMT2APOLB
SCHEMBL3555342 0.90 MAPK1 (0.46) CARM1PRMT6MEN1KMT2APOLB
SCHEMBL3557299 0.85 CCR3 (0.67) MEN1KMT2APOLBRAB9A
SCHEMBL4853518 0.85 UTS2R (0.67) CARM1PRMT6MEN1KMT2APRCP
SCHEMBL3563192 0.83 KDM4E (0.46) MEN1KMT2APOLBMAPTNPSR1
SCHEMBL27661919 0.83 CARM1 (0.56) CARM1PRMT6MEN1KMT2APOLB
SCHEMBL301836 0.82 KDM4E (0.45) MEN1KMT2APOLBMAPTDRD2
SCHEMBL3556286 0.82 KDM4E (0.45) MEN1KMT2APOLBMAPTDRD2
SCHEMBL301835 0.81 POLB (0.47) MEN1KMT2APOLBMAPK1MAPT
SCHEMBL3565549 0.80 HTR2A (0.49) MEN1KMT2APOLBMAPTDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750161-B2 Pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2010-07-06 US disclosed
US-20070043081-A1 Novel pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043081-A1 Novel pyridine derivatives P2RY4, P2RX6, P2RX4 CARM1 4731/4885PRMT6 3134/4885MEN1 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.